FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132803064> ?p ?o ?g. }

• W3132803064 endingPage "1672" @default.
• W3132803064 startingPage "1663" @default.
• W3132803064 abstract "Objective To evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis (PsA) in whom minimal disease activity (MDA) has been achieved after open‐label ixekizumab treatment. Methods SPIRIT‐P3 was a multicenter, randomized, double‐blind withdrawal study of biologic treatment–naive adult patients with PsA who were treated with open‐label ixekizumab for 36 weeks (160 mg at week 0, then 80 mg every 2 weeks). Patients in whom MDA was sustained for >3 consecutive months were randomized 1:1, between weeks 36 and 64, to undergo blinded withdrawal of ixekizumab treatment (placebo) or to continue ixekizumab treatment every 2 weeks up to week 104. The primary efficacy end point was time to relapse (loss of MDA) for randomized patients. Patients who experienced a relapse were re‐treated with ixekizumab every 2 weeks up to week 104. Results A total of 394 patients were enrolled and received open‐label ixekizumab every 2 weeks. Of those patients, 158 (40%) achieved sustained MDA and were randomized to undergo withdrawal of ixekizumab treatment (placebo every 2 weeks; n = 79) or to continue ixekizumab treatment every 2 weeks (n = 79). Disease relapse occurred more rapidly with treatment withdrawal (median 22.3 weeks [95% confidence interval (95% CI) 16.1–28.3]) compared to those who continued treatment with ixekizumab (median not estimable; P < 0.0001). Sixty‐seven patients (85%) compared to 30 patients (38%) experienced relapse in the placebo group and the continued treatment group, respectively. Median time to achieving MDA again with re‐treatment was 4.1 weeks (95% CI 4.1–4.3); in 64 of 67 patients (96%) who experienced relapse with treatment withdrawal, MDA was achieved again with re‐treatment. Safety was consistent with the known safety profile for ixekizumab. Conclusion Continued ixekizumab therapy is superior to ixekizumab withdrawal in maintaining low disease activity in biologic treatment–naive patients with PsA. Re‐treatment with ixekizumab following a relapse may restore disease control in cases of treatment interruption." @default.
• W3132803064 created "2021-03-01" @default.
• W3132803064 creator A5000010047 @default.
• W3132803064 creator A5014045275 @default.
• W3132803064 creator A5020923397 @default.
• W3132803064 creator A5023549100 @default.
• W3132803064 creator A5029741606 @default.
• W3132803064 creator A5032261051 @default.
• W3132803064 creator A5039987199 @default.
• W3132803064 creator A5044302023 @default.
• W3132803064 creator A5047849105 @default.
• W3132803064 creator A5058629132 @default.
• W3132803064 creator A5076364548 @default.
• W3132803064 creator A5077422183 @default.
• W3132803064 creator A5081778211 @default.
• W3132803064 creator A5085522760 @default.
• W3132803064 creator A5088310789 @default.
• W3132803064 creator A5090569050 @default.
• W3132803064 date "2021-08-06" @default.
• W3132803064 modified "2023-09-30" @default.
• W3132803064 title "Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study" @default.
• W3132803064 cites W117382359 @default.
• W3132803064 cites W1967501597 @default.
• W3132803064 cites W1985004174 @default.
• W3132803064 cites W2000688433 @default.
• W3132803064 cites W2004143788 @default.
• W3132803064 cites W2054242247 @default.
• W3132803064 cites W2064807058 @default.
• W3132803064 cites W2066227212 @default.
• W3132803064 cites W2067327580 @default.
• W3132803064 cites W2083180635 @default.
• W3132803064 cites W2083707884 @default.
• W3132803064 cites W2108490937 @default.
• W3132803064 cites W2113717019 @default.
• W3132803064 cites W2119067278 @default.
• W3132803064 cites W2119275077 @default.
• W3132803064 cites W2122920811 @default.
• W3132803064 cites W2152553239 @default.
• W3132803064 cites W2157270348 @default.
• W3132803064 cites W2194197257 @default.
• W3132803064 cites W2203272329 @default.
• W3132803064 cites W2339525054 @default.
• W3132803064 cites W2512436288 @default.
• W3132803064 cites W2575563373 @default.
• W3132803064 cites W2620369605 @default.
• W3132803064 cites W2741797984 @default.
• W3132803064 cites W2745119752 @default.
• W3132803064 cites W2759276628 @default.
• W3132803064 cites W2773179393 @default.
• W3132803064 cites W2883072230 @default.
• W3132803064 cites W2889426137 @default.
• W3132803064 cites W2967720956 @default.
• W3132803064 cites W3004681236 @default.
• W3132803064 doi "https://doi.org/10.1002/art.41716" @default.
• W3132803064 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8457232" @default.
• W3132803064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33682378" @default.
• W3132803064 hasPublicationYear "2021" @default.
• W3132803064 type Work @default.
• W3132803064 sameAs 3132803064 @default.
• W3132803064 citedByCount "11" @default.
• W3132803064 countsByYear W31328030642021 @default.
• W3132803064 countsByYear W31328030642022 @default.
• W3132803064 countsByYear W31328030642023 @default.
• W3132803064 crossrefType "journal-article" @default.
• W3132803064 hasAuthorship W3132803064A5000010047 @default.
• W3132803064 hasAuthorship W3132803064A5014045275 @default.
• W3132803064 hasAuthorship W3132803064A5020923397 @default.
• W3132803064 hasAuthorship W3132803064A5023549100 @default.
• W3132803064 hasAuthorship W3132803064A5029741606 @default.
• W3132803064 hasAuthorship W3132803064A5032261051 @default.
• W3132803064 hasAuthorship W3132803064A5039987199 @default.
• W3132803064 hasAuthorship W3132803064A5044302023 @default.
• W3132803064 hasAuthorship W3132803064A5047849105 @default.
• W3132803064 hasAuthorship W3132803064A5058629132 @default.
• W3132803064 hasAuthorship W3132803064A5076364548 @default.
• W3132803064 hasAuthorship W3132803064A5077422183 @default.
• W3132803064 hasAuthorship W3132803064A5081778211 @default.
• W3132803064 hasAuthorship W3132803064A5085522760 @default.
• W3132803064 hasAuthorship W3132803064A5088310789 @default.
• W3132803064 hasAuthorship W3132803064A5090569050 @default.
• W3132803064 hasBestOaLocation W31328030642 @default.
• W3132803064 hasConcept C126322002 @default.
• W3132803064 hasConcept C142724271 @default.
• W3132803064 hasConcept C168563851 @default.
• W3132803064 hasConcept C204787440 @default.
• W3132803064 hasConcept C27081682 @default.
• W3132803064 hasConcept C2776260265 @default.
• W3132803064 hasConcept C2777077863 @default.
• W3132803064 hasConcept C2779745271 @default.
• W3132803064 hasConcept C2779786854 @default.
• W3132803064 hasConcept C71924100 @default.
• W3132803064 hasConceptScore W3132803064C126322002 @default.
• W3132803064 hasConceptScore W3132803064C142724271 @default.
• W3132803064 hasConceptScore W3132803064C168563851 @default.
• W3132803064 hasConceptScore W3132803064C204787440 @default.
• W3132803064 hasConceptScore W3132803064C27081682 @default.
• W3132803064 hasConceptScore W3132803064C2776260265 @default.
• W3132803064 hasConceptScore W3132803064C2777077863 @default.

• next